Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27402550 | 0.89 | PLA2G1B (0.42) | PLA2G1BPLA2G2AALDH1A1TDP1CA12 | |
| SCHEMBL13106842 | 0.85 | PLA2G1B (0.35) | PLA2G1BPLA2G2AKCNH2 | |
| SCHEMBL15203102 | 0.82 | ALDH1A1 (0.50) | PLA2G1BPLA2G2AALDH1A1TDP1KCNH2 | |
| SCHEMBL27306915 | 0.81 | PLA2G1B (0.32) | PLA2G1BPLA2G2A | |
| SCHEMBL15418391 | 0.81 | DNM1 (0.44) | PLA2G1BPLA2G2AALDH1A1TDP1CA12 | |
| SCHEMBL4366899 | 0.79 | ALDH1A1 (0.52) | PLA2G1BPLA2G2AALDH1A1TDP1KCNH2 | |
| SCHEMBL16577644 | 0.79 | PLA2G1B (0.41) | PLA2G1BPLA2G2AMAPTCA12CA1 | |
| SCHEMBL628733 | 0.79 | ALDH1A1 (0.52) | PLA2G1BPLA2G2AALDH1A1TDP1KCNH2 | |
| SCHEMBL5948663 | 0.79 | PLA2G1B (0.36) | PLA2G1BPLA2G2A | |
| SCHEMBL5949196 | 0.79 | PLA2G1B (0.31) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | PLA2G1B 4511/4885PLA2G2A 4446/4885MAPT 2877/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | PLA2G1B 2035/4885PLA2G2A 2459/4885MAPT 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.